Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Moxifloxacin hydrochloride
Drug ID BADD_D01502
Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Indications and Usage For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Marketing Status approved; investigational
ATC Code J01MA14; S01AE07
DrugBank ID DB00218
KEGG ID D00874
MeSH ID D000077266
PubChem ID 101526
TTD Drug ID D0ZV0Z
NDC Product Code 48943-0025; 55111-064; 58032-0131; 40032-034; 60429-893; 50370-0001; 51927-4833; 51991-943; 72789-037; 29967-0005; 49574-522; 63323-850; 65862-627; 0093-7387; 50090-4100; 70518-3738; 51927-0167; 0781-7135; 49587-106; 50090-4058; 66298-8507; 67296-1616; 67457-323; 72789-038; 13668-201; 0078-0939; 65862-603; 68084-722; 0832-1410; 50268-576; 51927-0089; 57237-156
UNII C53598599T
Synonyms Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039
Chemical Information
Molecular Formula C21H25ClFN3O4
CAS Registry Number 186826-86-8
SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertension24.08.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperuricaemia14.09.01.003--
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypochromic anaemia01.03.02.004--Not Available
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypokalaemia14.05.03.002--
Hypomenorrhoea05.05.01.006; 21.01.02.002--Not Available
Hypophosphataemia14.04.03.001--
Hypoproteinaemia14.10.01.003; 09.01.02.004--Not Available
Hypotension24.06.03.002--
Hypotonia15.05.04.008; 17.05.02.002--Not Available
Immune system disorder10.02.01.001--Not Available
Immunoglobulins increased13.06.05.005--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Injection site hypersensitivity10.01.03.017; 08.02.03.006; 12.07.03.006--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intentional self-injury19.12.01.002; 12.01.08.036--Not Available
International normalised ratio abnormal13.01.02.029--Not Available
International normalised ratio decreased13.01.02.007--Not Available
International normalised ratio increased13.01.02.008--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Keratitis06.04.02.002--
Laboratory test abnormal13.18.01.001--Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 14 Pages